CETRAXAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CETRAXAL (CETRAXAL).
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. |
| Excretion | CETRAXAL is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. Approximately 70% of the dose is recovered in urine within 24 hours, with an additional 15% recovered in feces via biliary excretion, totaling ~85% elimination. The remainder is metabolized hepatically to inactive metabolites. |
| Half-life | The terminal elimination half-life is approximately 2.5–3.0 hours in patients with normal renal function (creatinine clearance >80 mL/min). This short half-life supports twice-daily dosing for most indications. In renal impairment (CrCl 20–50 mL/min), half-life extends to 6–9 hours, requiring dose adjustment. |
| Protein binding | CETRAXAL is approximately 98–99% bound to plasma proteins, primarily to albumin. The high protein binding limits distribution and prolongs half-life; only the unbound fraction (1–2%) is pharmacologically active. |
| Volume of Distribution | The apparent volume of distribution (Vd) is approximately 0.15–0.20 L/kg, indicating limited extravascular distribution (mainly in extracellular fluid). This low Vd reflects high protein binding and poor tissue penetration, except in inflamed tissues where distribution may increase modestly. |
| Bioavailability | Oral: Absolute bioavailability is approximately 85–90% due to first-pass metabolism (10–15% extraction). IV: 100%. Topical otic: Systemic bioavailability is negligible (<1%) due to minimal absorption through intact tympanic membrane; however, absorption may increase if the membrane is perforated. |
| Onset of Action | Oral: Onset of clinical effect (pain relief, fever reduction) occurs within 30–60 minutes after oral administration. Intravenous: Onset within 5–10 minutes after IV bolus. Topical (otic solution): Onset of local anesthetic effect within 2–5 minutes after instillation in the ear. |
| Duration of Action | Oral/IV: Duration of analgesic and antipyretic effect is approximately 4–6 hours, corresponding to the dosing interval. Topical otic: Duration of local anesthesia is 15–30 minutes, with antimicrobial effect persisting for 6–8 hours due to sustained drug levels in ear canal. |
1-2 drops in affected ear(s) twice daily for 7 days; otic solution.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment. |
| Pediatric use | Children 6 months and older: 1-2 drops in affected ear(s) twice daily for 7 days; otic solution. |
| Geriatric use | No specific dose adjustment; use same dosing as adults with caution for impaired hepatic/renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CETRAXAL (CETRAXAL).
| Breastfeeding | CETRAXAL (cetirizine) is excreted into human breast milk in small amounts. The milk-to-plasma ratio is approximately 0.25-0.6. In infants, the estimated daily dose via breast milk is about 2-5% of the maternal weight-adjusted dose, which is generally considered compatible with breastfeeding. However, monitor for signs of sedation or irritability in the infant. |
| Teratogenic Risk | CETRAXAL (cetirizine) is an antihistamine classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but adequate and well-controlled human studies in pregnant women are lacking. Based on available data, first-trimester use is not associated with a major increase in congenital anomalies. Second- and third-trimester use is considered low risk. However, caution is advised, and use only if clearly needed. |
■ FDA Black Box Warning
Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture in all ages; avoid with concomitant corticosteroids.
| Serious Effects |
Hypersensitivity to ciprofloxacin or any quinolone.
| Precautions | Avoid prolonged use; may result in overgrowth of non-susceptible organisms including fungi. Discontinue if sensitization or severe irritation occurs. |
| Food/Dietary | No significant food interactions with otic ciprofloxacin. Systemic absorption minimal, so no dietary restrictions necessary. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring is required beyond routine prenatal care. Observe for maternal adverse effects such as sedation, dizziness, or dry mouth. In neonates, especially with third-trimester exposure, monitor for potential withdrawal symptoms or paradoxical excitation. |
| Fertility Effects | CETRAXAL (cetirizine) is not known to have significant effects on fertility in humans. Animal studies showed no impairment at doses up to 25 times the clinical dose. Case reports are lacking; theoretical risk is minimal. |
| CETRAXAL (ciprofloxacin otic) is approved for acute otitis externa and acute otitis media with tympanostomy tubes. Use for 7 days. Avoid in patients with known hypersensitivity to quinolones. Not for systemic use. May cause local irritation. Assess tympanic membrane integrity before use. |
| Patient Advice | Warm the bottle in hands for 1-2 minutes before use to avoid dizziness. · Instill prescribed number of drops into the affected ear while lying down with ear facing up. · Remain lying down for 5 minutes after instillation to allow penetration. · Do not touch the dropper tip to ears or surfaces to avoid contamination. · Complete full course even if symptoms improve. · Report worsening pain, rash, or signs of allergy immediately. · Avoid swimming or water exposure until infection resolves. |